John H Fetting
Overview
Explore the profile of John H Fetting including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
750
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wolff J, Aufill J, Echavarria D, Blackford A, Connolly R, Fetting J, et al.
NPJ Breast Cancer
. 2021 Feb;
7(1):14.
PMID: 33579966
We examined the effects of a communication intervention to engage family care partners on patient portal (MyChart) use, illness understanding, satisfaction with cancer care, and symptoms of anxiety in a...
2.
Sheng J, Santa-Maria C, Mangini N, Norman H, Couzi R, Nunes R, et al.
JCO Oncol Pract
. 2020 Jul;
16(10):665-674.
PMID: 32603252
The COVID-19 pandemic has rapidly changed delivery of cancer care. Many nonurgent surgeries are delayed to preserve hospital resources, and patient visits to health care settings are limited to reduce...
3.
Wolff J, Aufill J, Echavarria D, Heughan J, Lee K, Connolly R, et al.
Breast Cancer Res Treat
. 2019 Jun;
177(1):127-136.
PMID: 31165374
Purpose: Family is often overlooked in cancer care. We developed a patient-family agenda setting intervention to engage family in cancer care communication. Methods: We conducted a pilot randomized controlled trial...
4.
Santa-Maria C, Bardia A, Blackford A, Snyder C, Connolly R, Fetting J, et al.
Breast Cancer Res Treat
. 2018 May;
171(1):121-129.
PMID: 29752687
Purpose: Aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) are common adverse events of AIs often leading to drug discontinuation. We initiated a prospective clinical trial to evaluate whether bisphosphonates are associated with...
5.
Kim H, Umbricht C, Illei P, Cimino-Mathews A, Cho S, Chowdhury N, et al.
J Clin Oncol
. 2016 Dec;
34(36):4390-4397.
PMID: 27998227
Purpose Gene expression profiling assays are frequently used to guide adjuvant chemotherapy decisions in hormone receptor-positive, lymph node-negative breast cancer. We hypothesized that the clinical value of these new tools...
6.
Connolly R, Li H, Jankowitz R, Zhang Z, Rudek M, Jeter S, et al.
Clin Cancer Res
. 2016 Dec;
23(11):2691-2701.
PMID: 27979916
In breast cancer models, combination epigenetic therapy with a DNA methyltransferase inhibitor and a histone deacetylase inhibitor led to reexpression of genes encoding important therapeutic targets, including the estrogen receptor...
7.
Connolly R, Leal J, Goetz M, Zhang Z, Zhou X, Jacobs L, et al.
J Nucl Med
. 2014 Dec;
56(1):31-7.
PMID: 25476537
Unlabelled: Epigenetic modifiers, including the histone deacetylase inhibitor vorinostat, may sensitize tumors to chemotherapy and enhance outcomes. We conducted a multicenter randomized phase II neoadjuvant trial of carboplatin and nanoparticle...
8.
Tevaarwerk A, Wang M, Zhao F, Fetting J, Cella D, Wagner L, et al.
J Clin Oncol
. 2014 Oct;
32(35):3948-58.
PMID: 25349302
Purpose: The effects of ovarian function suppression (OFS) on survival and patient-reported outcomes were evaluated in a phase III trial in which premenopausal women were randomly assigned to tamoxifen with...
9.
Rudek M, Connolly R, Hoskins J, Garrett-Mayer E, Jeter S, Armstrong D, et al.
Breast Cancer Res Treat
. 2013 Apr;
139(1):135-43.
PMID: 23588952
The pro-drug capecitabine is approved for treatment of anthracycline- and paclitaxel-resistant metastatic breast cancer. However, toxicity and large interpatient pharmacokinetic variability occur despite body surface area (BSA)-dosing. We hypothesized that...
10.
Cimino-Mathews A, Subhawong A, Illei P, Sharma R, Halushka M, Vang R, et al.
Hum Pathol
. 2013 Feb;
44(7):1341-9.
PMID: 23375642
GATA3 plays an integral role in breast luminal cell differentiation and is implicated in breast cancer progression. GATA3 immunohistochemistry is a useful marker of breast cancer; however, its use in...